Company news

Lixte Biotechnology Holdings, Inc. news in 2021

Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Lixte Biotechnology Holdings, Inc. announces that enrollment has resumed in National Cancer Institute’s trial to determine ability of Lixte compound LB-100 to enter recurrent, malignant brain tumors

November 21, 2021

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

October 12, 2021

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction

August 16, 2021

Lixte Biotechnology’s LB-100 elicits anti- tumor activity in small lung cancer models by unique mechanisms in an important pre-clinical study

August 2, 2021

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

June 1, 2021

Lixte Biotechnology Holdings, Inc. announces the appointment of Regina Brown to its board of directors

May 11, 2021

Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

April 12, 2021

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

March 2, 2021

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

March 1, 2021

Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

February 28, 2021

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

February 23, 2021

Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

January 18, 2021